<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">85246</article-id><article-id pub-id-type="doi">10.7554/eLife.85246</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>Dalpiciclib partially abrogates ER signaling activation induced by pyrotinib in HER2<sup>+</sup>HR<sup>+</sup> breast cancer</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-254343"><name><surname>Bu</surname><given-names>Jiawen</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-217304"><name><surname>Zhang</surname><given-names>Yixiao</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-254347"><name><surname>Niu</surname><given-names>Nan</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-254344"><name><surname>Bi</surname><given-names>Kewei</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-208845"><name><surname>Sun</surname><given-names>Lisha</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-4095-5026</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-217303"><name><surname>Qiao</surname><given-names>Xinbo</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6759-921X</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-254345"><name><surname>Wang</surname><given-names>Yimin</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-254346"><name><surname>Zhang</surname><given-names>Yinan</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-254348"><name><surname>Jiang</surname><given-names>Xiaofan</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-254349"><name><surname>Wang</surname><given-names>Dan</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-217305"><name><surname>Ma</surname><given-names>Qingtian</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-254350"><name><surname>Li</surname><given-names>Huajun</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-156274"><name><surname>Liu</surname><given-names>Caigang</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-2083-235X</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf3"/></contrib><aff id="aff1"><institution content-type="dept">Department of Oncology</institution>, <institution>Shengjing Hospital of China Medical Universit</institution>, <addr-line><named-content content-type="city">Shenyang</named-content></addr-line>, <country>China</country></aff><aff id="aff2"><institution content-type="dept">Department of Oncology</institution>, <institution>Shengjing Hospital of China Medical University</institution>, <addr-line><named-content content-type="city">Shenyang</named-content></addr-line>, <country>China</country></aff><aff id="aff3"><institution content-type="dept">Clinical Research and Development</institution>, <institution>Jiangsu Hengrui Pharmaceuticals Co Ltd</institution>, <addr-line><named-content content-type="city">Shanghai</named-content></addr-line>, <country>China</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-217314"><name><surname>Yang</surname><given-names>Yongliang</given-names></name><role>Reviewing editor</role><aff><institution>Dalian University of Technology</institution>, <country>China</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>angel-s205@163.com</email> (CL);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>05</day><month>01</month><year>2023</year></pub-date><volume>12</volume><elocation-id>e85246</elocation-id><history><date date-type="received"><day>29</day><month>11</month><year>2022</year></date><date date-type="accepted"><day>29</day><month>12</month><year>2022</year></date></history><permissions><copyright-statement>Â© 2022, Bu et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Bu et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-85246-v1.pdf"/><abstract><p>Recent evidences from clinical trials (NCT04486911) revealed that the combination of pyrotinib, letrozole and dalpiciclib exerted optimistic therapeutic effect in treating HER2<sup>+</sup>HR<sup>+</sup> breast cancer, however, the underlying molecular mechanism remained elusive. Through the drug sensitivity test, the drug combination efficacy of pyrotinib, tamoxifen and dalpiciclib to BT474 cells were tested. The underlying molecular mechanisms were investigated using immunofluorescence, Western blot analysis, immunohistochemical staining and cell cycle analysis. Potential risk factor which may indicate the responsiveness to drug treatment in HER2<sup>+</sup>/HR<sup>+</sup> breast cancer was identified using RNA-sequence and evaluated using immunohistochemical staining and in vivo drug susceptibility test. We found that pyrotinib combined with dalpiciclib exerted better cytotoxic efficacy than pyrotinib combined with tamoxifen in BT474 cells. Degradation of HER2 could enhance ER nuclear transportation, activating ER signaling pathway in BT474 cells whereas dalpiciclib could partially abrogate this process. This may be the underlying mechanism by which combination of pyrotinib, tamoxifen and dalpiciclib exerted best cytotoxic effect. Furthermore, CALML5 was revealed to be a risk factor in the treatment of HER2<sup>+</sup>/HR<sup>+</sup> breast cancer and the usage of dalpiciclib might overcome the drug resistance to pyrotinib + tamoxifen due to CALML5 expression. Our study provided evidence that the usage of dalpiciclib in the treatment of HER2<sup>+</sup>/HR<sup>+</sup> breast cancer could partially abrogate the estrogen signaling pathway activation caused by anti-HER2 therapy and revealed that CALML5 could serve as a risk factor in the treatment of HER2<sup>+</sup>/HR<sup>+</sup> breast cancer.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>U20A20381</award-id><principal-award-recipient><name><surname>Liu</surname><given-names>Caigang</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source><award-id>81872159</award-id><principal-award-recipient><name><surname>Liu</surname><given-names>Caigang</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Huajun Li, is affiliated with Jiangsu Hengrui Pharmaceuticals Co. Ltd and the author has no other competing interests to declare..</p></fn><fn fn-type="conflict" id="conf3"><p>Caigang Liu, Reviewing editor, <italic>eLife</italic>.</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: The animal study was approved by the Ethics Committee of Shengjing Hospital of China Medical University (Permit Number: 2020PS318K). The pdf permission document have been uploaded as a Supporting Zip Document.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>Sequencing data have been deposited in GSA database (https://ngdc.cncb.ac.cn/) under accession link: https://ngdc.cncb.ac.cn/omix/view/OMIX002504All data generated or analysed during the study are included in the manuscript and figure supplements.Source data files have been provided for Figure 1-Figure 4 as well as all the Figure supplements.Raw gel data for Figure 4 and Figure 2-figure supplement 1 was uploaded as source data files corresponding to the figures.</p><p>The following datasets were generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><collab>Caigang Liu</collab></person-group><year iso-8601-date="2022">2022</year><source>Expression matrix of BT474 cells treated with different durgs and their combination</source><ext-link ext-link-type="uri" xlink:href="https://ngdc.cncb.ac.cn/omix/select-edit/OMIX002504">https://ngdc.cncb.ac.cn/omix/select-edit/OMIX002504</ext-link><comment>GSA database, OMIX002504</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-85246-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>